ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY ), a leading biomedical company focused on addressing the most pressing issues of women worldwide with a broad portfolio of in-office, accessible, and innovative solutions. medical and diagnostic drugs, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a panel discussion at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at. Maxim Group. The conference is being held on October 15 – 17, 2024.
Kathy Lee-Sepsick and Dov Elefant, Chief Financial Officer, will be available for one-on-one meetings throughout the meeting.
About Femasys
Femasys is a leading biomedical company focused on addressing the critical unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative treatment and diagnostic solutions, including leading product innovations and FDA-cleared products. FemaSeed® Intratubal Insemination, a fertility treatment designed to deliver sperm directly at the point of conception, has been cleared by the FDA and has received regulatory approval in Canada and Europe. FemBloc® Permanent birth control during clinical development is the first and only non-surgical, in-office, birth control method intended to be a safer option for women at a lower cost than the traditional surgical alternative. The Company has developed diagnostic products that are compatible with those that it has obtained approval to sell in the US, Canada, Europe, and other former US territories, and are ready-to-sell due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® Mini fallopian tube assessment with ultrasound, which can be used in conjunction with FemCath.®intrauterine catheter for selective fallopian tube evaluation, and FemCerv®endocervical tissue sampler for cervical cancer screening. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward Looking Words
This press release contains forward-looking statements that are subject to significant risks and uncertainties. Forward-looking statements can be identified by words such as “would,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “expect,” “aim,” “believe,” “prove ,” “possible,” “hope,” or “continue” or negative expressions of these words or similar words, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to uncertainties, risks and assumptions, many of which are beyond our control, are difficult to predict and could cause actual results to differ materially from our expectations. Furthermore, certain forward-looking statements are based on assumptions about future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our product manufacturers and programs, and to successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate the safety and efficacy of product candidates and other positive outcomes; predictions regarding the potential market for our products and product representatives; our ability to market our products and competitors’ products, or the effect of delays in marketing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our performance in doing so; and other risks and uncertainties described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in press releases are made as of today, and Femassy undertakes no obligation to update such information unless required under applicable law.
Contacts:
Investors:
Matt Blazei
IR@femasis.com
Media:
Central Waldenburg
Media@femasis.com
#Femasys #participate #Fireside #Chat #Maxim #Healthcare #Virtual #Summit